Displaying drugs 1426 - 1450 of 1959 in total
INM004
INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.
Investigational
MUL001
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
WU-CART-007
WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Investigational
PRA023
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
FINLAY-FR-1
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute . It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and...
Investigational
Dimethyl Propionate Ester Heme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoate ... methoxy-3-oxopropyl)-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
AER001
AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.
Investigational
trans NV-04
trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Investigational
MAHDL01
MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.
Investigational
DAR-0100A
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
GTA002
Investigational
GDX012
Investigational
FCR001
FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational
Verdoheme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3,5,8,10,12,14,16,18(22),19,21(24)-decaen-22-ylium ... diethenyl-5,10,14,20-tetramethyl-7-oxa-2,22lambda5,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
KTH-222
Investigational
LFF-571
LFF571 has been used in trials studying the treatment of Moderate Clostridium Difficile Infection.
Investigational
Matched Iupac: … pentathia-7,17,24,31,34,39,40,41,42,43-decaazaheptacyclo[34.2.1.1^{2,5}.1^{12,15}.1^{19,22}.1^{26,29}.0^ ... {6,11}]tritetraconta-1(38),2(43),4,6,8,10,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazol …
Cinolazepam
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Experimental
XMMME-001-RTA
Investigational
Siroheme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3,6,8,11,13,15,17,19,21(24)-nonaen-4-yl]propanoic acid ... -tetrakis(carboxymethyl)-5,10-dimethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
MK-6325
MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Investigational
Matched Iupac: … {5,14}.0^{7,12}.0^{20,24}.0^{36,38}]tritetraconta-5,7(12),8,10,13,34-hexaene-38-carboxamide ... methylcyclopropyl)sulfonyl]-26,40,42-trioxo-4,25-dioxa-1,6,13,27,39-pentaazaheptacyclo[26.13.1.1^{3,41}.0^ …
ASP-7317
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
Investigational
AZD0947
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Displaying drugs 1426 - 1450 of 1959 in total